Lisanti Capital Growth LLC acquired a new stake in Repligen Corporation (NASDAQ:RGEN – Free Report) in the 3rd quarter, Holdings Channel.com reports. The institutional investor acquired 21,115 shares of the biotechnology company’s stock, valued at approximately $4,059,000.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in RGEN. North Dakota State Investment Board lifted its holdings in shares of Repligen by 4.1% during the third quarter. North Dakota State Investment Board now owns 1,630 shares of the biotechnology company’s stock worth $313,000 after purchasing an additional 64 shares during the period. Farther Finance Advisors LLC raised its position in shares of Repligen by 35.5% during the 3rd quarter. Farther Finance Advisors LLC now owns 374 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 98 shares during the last quarter. ABS Investment Management LLC acquired a new stake in shares of Repligen during the 2nd quarter worth about $191,016,000. State of Alaska Department of Revenue grew its stake in Repligen by 2.9% in the 3rd quarter. State of Alaska Department of Revenue now owns 5,346 shares of the biotechnology company’s stock worth $1,027,000 after acquiring an additional 150 shares during the period. Finally, Crossmark Global Holdings Inc. boosted its position in shares of Repligen by 3.5% in the third quarter. Crossmark Global Holdings Inc. now owns 4,525 shares of the biotechnology company’s stock worth $870,000 after acquiring an additional 152 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several research firms have issued reports on RGEN. Canaccord Genuity Group boosted their price objective on shares of Repligen from $145.00 to $180.00 and gave the stock a “hold” rating in a research note on Monday, October 19th. Barclays upped their price target on shares of Repligen from $175.00 to $225.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Wells Fargo & Company raised their price objective on shares of Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday, July 30th. Zacks Research downgraded shares of Repligen from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. Finally, Royal Bank Of Canada upped their target price on shares of Repligen from $185.00 to $200.00 and gave the company an “outperform” rating in a research note on Wednesday, October 28th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Repligen has an average rating of “Moderate Buy” and an average price target of $178.57.
Read Our Latest Stock Analysis on Repligen
Repligen Stock Down 0.8%
Shares of Repligen stock opened at $172.62 on Thursday. The business’s fifty day moving average price is $177.31 and its two-hundred day moving average price is $145.63. The company has a debt-to-equity ratio of 0.27, a current ratio of 9.88 and a quick ratio of 8.43. The company has a market capitalization of $11.03 billion, a P/E ratio of 85.28, a PEG ratio of 2.98 and a beta of 1.11. Repligen Corporation has a 1-year low of $100.99 and a 1-year high of $198.87.
Repligen (NASDAQ:RGEN – Get Free Report) last released its quarterly earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.07. Repligen had a positive return on equity of 5.49% and a negative net margin of 1.47%. The company had revenue of $209.31 million during the quarter, compared to analysts’ expectations of $206.70 million. During the same quarter in the prior year, the business posted $0.46 earnings per share. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. As a group, research analysts forecast that Repligen Corporation will post 2.07 EPS for the current year.
Repligen Company Profile
Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.
Featured Articles
- Five stocks we like better than Repligen
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN – Free Report).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
